Provectus Pharmaceuticals(PVCT)
$0.05+0.00 (+7.14%)
PVCT
Provectus Pharmaceuticals financials statements
$0.05
At close:+0.00 (+7.14%)
Provectus Pharmaceuticals (PVCT) Ratios
81 Followers
Provectus Pharmaceuticals Ratios
PVCT's free cash flow for Q3 2026 was $-859.60K. For the 2026 fiscal year, PVCT's free cash flow was decreased by $-5.00 and operating cash flow was $-859.60K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.08 | 0.14 | 0.15 | 0.23 | 0.45 |
| Quick Ratio | 0.08 | 0.14 | 0.15 | 0.23 | 0.45 |
| Cash Ratio | 0.04 | 0.04 | 0.01 | 0.00 | 0.09 |
| Solvency Ratio | -0.78 | -0.68 | -0.34 | -0.42 | -0.71 |
| Operating Cash Flow Ratio | -0.48 | -0.47 | -0.29 | -0.37 | -0.13 |
| Short-Term Operating Cash Flow Coverage | -1.18 | -1.04 | -0.87 | -1.44 | -0.58 |
| Net Current Asset Value | $ -6.43M | $ -6.00M | $ -7.68M | $ -6.37M | $ -4.26M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 4.27 | 3.16 | 2.09 | 1.09 | 0.50 |
| Debt-to-Equity Ratio | -0.47 | -0.53 | -0.40 | -0.36 | -0.42 |
| Debt-to-Capital Ratio | -0.90 | -1.15 | -0.66 | -0.56 | -0.71 |
| Long-Term Debt-to-Capital Ratio | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.11 | -0.17 | -0.19 | -0.33 | -0.84 |
| Debt Service Coverage Ratio | -1.59 | -1.33 | -0.91 | -1.48 | -1.71 |
| Interest Coverage Ratio | -23.03 | -16.54 | -13.42 | -20.94 | -4.86 |
| Debt to Market Cap | 0.12 | 0.06 | 0.07 | 0.05 | 0.08 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Net Debt to EBITDA | -0.56 | -0.64 | -1.02 | -0.66 | -0.23 |
| Profitability Margins | |||||
| Gross Profit Margin | 99.45% | 98.84% | -204.77% | 93.55% | 0.00% |
| EBIT Margin | -1441.28% | -734.36% | -520.16% | -346.60% | 0.00% |
| EBITDA Margin | -1440.73% | -733.22% | -518.55% | -340.13% | 0.00% |
| Operating Profit Margin | -1441.28% | -640.81% | -520.16% | -346.60% | 0.00% |
| Pretax Profit Margin | -1637.90% | -773.13% | -558.89% | -359.44% | 0.00% |
| Net Profit Margin | -1615.81% | -766.92% | -556.20% | -359.34% | 0.00% |
| Continuous Operations Profit Margin | -1637.90% | -771.62% | -556.20% | -359.44% | 0.00% |
| Net Income Per EBT | 98.65% | 99.20% | 99.52% | 99.97% | 100.00% |
| EBT Per EBIT | 113.64% | 120.65% | 107.45% | 103.70% | 118.58% |
| Return on Assets (ROA) | -778.61% | -470.36% | -214.10% | -174.45% | -157.68% |
| Return on Equity (ROE) | 86.17% | 79.42% | 40.85% | 57.06% | 132.31% |
| Return on Capital Employed (ROCE) | 78.13% | 66.25% | 38.33% | 55.69% | 111.58% |
| Return on Invested Capital (ROIC) | 145.74% | 141.75% | 63.20% | 85.71% | 194.86% |
| Return on Tangible Assets | -778.61% | -470.36% | -214.10% | -174.45% | -157.68% |
| Earnings Yield | -23.12% | -9.39% | -7.70% | -7.82% | -24.67% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 1171.66 | 2510.26 | 0.00 |
| Payables Turnover | 0.00 | 0.01 | 1.01 | 0.03 | 0.07 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.65 | 20.93 | 6.64 | 7.16 | 0.00 |
| Asset Turnover | 0.48 | 0.61 | 0.38 | 0.49 | 0.00 |
| Working Capital Turnover Ratio | -0.05 | -0.09 | -0.08 | -0.19 | 0.00 |
| Cash Conversion Cycle | -140322.22 | -56440.90 | -359.72 | -11985.24 | -4992.64 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.31 | 0.15 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 140322.22 | 56440.90 | 360.04 | 11985.39 | 4992.64 |
| Operating Cycle | 0.00 | 0.00 | 0.31 | 0.15 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 |
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -1285989.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -1285989.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -1.12 | -1.03 | -0.85 | -1.36 | -0.58 |
| Operating Cash Flow to Sales Ratio | -9.90 | -5.32 | -4.61 | -3.08 | 0.00 |
| Free Cash Flow Yield | -14.16% | -6.51% | -6.39% | -6.70% | -4.51% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.33 | -10.63 | -12.98 | -12.78 | -4.05 |
| Price-to-Sales (P/S) Ratio | 69.90 | 81.70 | 72.21 | 45.93 | 0.00 |
| Price-to-Book (P/B) Ratio | -3.73 | -8.46 | -5.30 | -7.29 | -5.36 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.06 | -15.35 | -15.66 | -14.94 | -22.16 |
| Price-to-Operating Cash Flow Ratio | -7.06 | -15.35 | -15.66 | -14.94 | -22.16 |
| Price-to-Earnings Growth (PEG) Ratio | -0.31 | -0.20 | 1.00 | 0.27 | 0.20 |
| Enterprise Value Multiple | -5.41 | -11.78 | -14.95 | -14.16 | -5.09 |
| Enterprise Value | 26.22M | 53.30M | 43.22M | 47.64M | 23.51M |
| EV to EBITDA | -5.41 | -11.78 | -14.95 | -14.16 | -5.09 |
| EV to Sales | 78.01 | 86.36 | 77.50 | 48.16 | 0.00 |
| EV to Free Cash Flow | -7.88 | -16.23 | -16.81 | -15.66 | -23.20 |
| EV to Operating Cash Flow | -7.88 | -16.23 | -16.81 | -15.66 | -23.20 |
| Tangible Book Value Per Share | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 |
| Shareholders’ Equity Per Share | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Tax Burden | 0.99 | 0.99 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.14 | 1.05 | 1.07 | 1.04 | 1.19 |
| Research & Development to Revenue | 5.64 | 3.23 | 3.14 | 2.42 | 0.00 |
| SG&A to Revenue | 11.11 | 5.10 | 2.34 | 2.05 | 0.00 |
| Stock-Based Compensation to Revenue | 3.68 | 2.08 | 0.01 | 0.00 | 0.00 |
| Income Quality | 0.61 | 0.69 | 0.83 | 0.86 | 0.18 |
Currency in USD

